title: Does induction chemoradiotherapy increase survival in patients with Pancoast tumour?
abstract: A best evidence topic in cardiothoracic surgery was written according to a structured protocol. The question addressed was whether induction (neoadjuvant) chemoradiotherapy (iCRT) compared with other therapeutic strategies improves survival in patients with Pancoast tumours. Altogether 248 papers were identified using the below-mentioned search. Ten of them represented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group, relevant outcomes and weaknesses were tabulated. Four studies were retrospective comparative studies of induction chemoradiotherapy and surgery (trimodal therapy) versus other therapeutic strategies. Two studies were retrospective and four were prospective investigating trimodal therapy. These papers comprised a total of 550 patients. The overall survival was better with trimodal therapy compared with RT (radiotherapy) followed by surgery group in all three comparative studies. The 2-year survival varied in the trimodal therapy group from 70 to 93%, in comparison to RT group where variation was from 22 to 49%. Five-year survival for trimodal therapy varied between 36.4 and 84% in the results of two comparative studies, compared with 11 and 49% for RT and surgery, respectively. One paper looked at survival in patients who underwent surgery alone [30% at 2-year and 20% at 4-year overall survival (OS)]. The 5-year OS in the retrospective group varied between 38 and 59%. Similar results were reported for the prospective group with 5-year OS between 44 and 56%. Despite a large variation in pCR (complete pathological response) (15-93%) and R0 (77-100%) reported, both represented a positive prognostic factor for survival. Three papers looked at the impact of staging following induction chemoradiotherapy. The majority of patients had T3 disease. An advantage in survival was seen in patients with early disease compared with advanced stage. No randomized controlled trials were identified. All the 10 articles suggested there was a benefit in trimodal therapy with improvement in overall survival. We conclude that combining induction chemoradiotherapy with surgery for Pancoast tumour may offer a survival benefit compared with radiotherapy with surgery or surgery alone.
authors.affiliation: Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK silviubuderi@yahoo.com.
authors.forename: Silviu I
authors.initials: SI
authors.lastname: Buderi
authors.affiliation: Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.
authors.forename: Michael
authors.initials: M
authors.lastname: Shackcloth
authors.affiliation: Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.
authors.forename: Steven
authors.initials: S
authors.lastname: Woolley
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D060828:Induction Chemotherapy / Q000379:methods*; D008297:Male; D010178:Pancoast Syndrome / Q000188:drug therapy* / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate / Q000639:trends; D006113:United Kingdom / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents
keywords: Chemoradiotherapy; Lung cancer; Pancoast tumour; Superior sulcus tumour; Survival